(2S)-2-[[cyclopropyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-3-methylbutanoic acid | 165315-67-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-[[cyclopropyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-3-methylbutanoic acid
• CAS: 165315-67-3
• 化学式: C₁₆H₂₅N₃O₃S
• 分子量: 339.459
• InChiKey: UGRUJNLKAXBZGT-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  111
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2S)-2-[[cyclopropyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-3-methylbutanoic acid 、 N-[(1R,4R)-4-氨基-5-苯基-1-(苄基)戊基]氨基甲酸 5-噻唑基甲基酯 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 以71%的产率得到thiazol-5-ylmethyl N-[(1R,4R)-1-benzyl-4-[[(2S)-2-[[cyclopropyl-[(2-isopropylthiazol-4-yl)methyl]carbamoyl]amino]-3-methyl-butanoyl]amino]-5-phenyl-pentyl]carbamate
  参考文献：
  名称：

  WO2008/10921

  摘要：

  公开号：
• 作为产物：
  描述：

  N-cyclopropyl-N-<(2-isopropyl-4-thiazolyl)methyl>amine 在 N,N-二异丙基乙胺 、 N,N'-羰基二咪唑 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 (2S)-2-[[cyclopropyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-3-methylbutanoic acid
  参考文献：
  名称：

  Structure–activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350)

  摘要：

  The HIV protease inhibitor (PI) ritonavir (RTV) has been widely used as a pharmacoenhancer for other PIs, which are substrates of cytochrome P450 3A (CYP3A). However the potent anti-HIV activity of ritonavir may limit its use as a pharmacoenhancer with other classes of anti-HIV agents. Ritonavir is also associated with limitations such as poor physicochemical properties. To address these issues a series of compounds with replacements at the P2 and/or P3 region was designed and evaluated as novel CYP3A inhibitors. Through these efforts, a potent and selective inhibitor of CYP3A, GS-9350 (cobicistat) with improved physiochemical properties was discovered. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.057

文献信息

• Modulators of pharmacokinetic properties of therapeutics
  申请人：GILEAD SCIENCES, INC.

  公开号：EP2487164A1

  公开（公告）日：2012-08-15

  The present application provides for a compound of Formula IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.

  本申请提供了IV式化合物，或其药学上可接受的盐、溶剂化合物和/或酯，含有这种化合物的组合物，包括该化合物的给药治疗方法，以及包括该化合物与至少一种额外治疗剂的联合给药治疗方法。
• [EN] RETROVIRAL PROTEASE INHIBITING COMPOUNDS<br/>[FR] COMPOSES INHIBANT DES PROTEASES RETROVIRALES
  申请人：ABBOTT LABORATORIES

  公开号：WO1994014436A1

  公开（公告）日：1994-07-07

  (EN) A retroviral protease inhibiting compound of formula (A) is disclosed.(FR) L'invention se rapporte à un composé inhibant des protéases rétrovirales, qui est présenté par la formule (A).

  一种抑制反转录病毒蛋白酶的化合物公式（A）已被披露。(法语)本发明涉及一种通过公式（A）表示的抑制反转录病毒蛋白酶的化合物。
• Retroviral protease inhibiting compounds
  申请人：Abbott Laboratories

  公开号：EP0727419A2

  公开（公告）日：1996-08-21

  A retroviral protease inhibiting compound of formula (A) is disclosed for use in combination with other active pharmaceutical agents for treating a human infected by HIV. Intermediates and processes useful in the manufacture of compounds of formula (A) are also disclosed.

  本发明公开了一种抑制逆转录病毒蛋白酶的式(A)化合物，该化合物可与其他活性药剂联合使用，用于治疗受艾滋病毒感染的人。还公开了用于制造式（A）化合物的中间体和工艺。
• Processes and intermediates for manufacturing retroviral protease inhibiting compounds
  申请人：ABBOTT LABORATORIES

  公开号：EP1090914A2

  公开（公告）日：2001-04-11

  A retroviral protease inhibiting compound of formula (A) is disclosed for use in combination with other active pharmaceutical agents for treating a human infected by HIV. Intermediates and processes useful in the manufacture of compounds of formula (A) are also disclosed.

  本发明公开了一种抑制逆转录病毒蛋白酶的式(A)化合物，该化合物可与其他活性药剂联合使用，用于治疗受艾滋病毒感染的人。还公开了用于制造式（A）化合物的中间体和工艺。
• MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS
  申请人：Gilead Sciences, Inc.

  公开号：EP2118082B1

  公开（公告）日：2014-10-01